Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000046933 | SCV000245905 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
CFTR- |
RCV000046933 | SCV001169252 | pathogenic | Cystic fibrosis | 2018-01-29 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV000046933 | SCV001582523 | pathogenic | Cystic fibrosis | 2020-04-30 | criteria provided, single submitter | clinical testing | This variant has been observed in individual(s) with CFTR-related conditions (PMID: 1284537, 21520337). This variant is also known as 3737delA in the literature. ClinVar contains an entry for this variant (Variation ID: 53777). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asp1202Alafs*9) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005031513 | SCV005666419 | pathogenic | Bronchiectasis with or without elevated sweat chloride 1; Cystic fibrosis; Hereditary pancreatitis; Congenital bilateral aplasia of vas deferens from CFTR mutation | 2024-04-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001831776 | SCV002075852 | pathogenic | CFTR-related disorder | 2017-03-17 | no assertion criteria provided | clinical testing |